Vendor Intelligence Report: Lumira

Published 2 Jul 2026. 23-page investigative report on who is behind Lumira: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 28 Finnrick lab tests, Lumira records 22 pass / 6 fail — a 79% overall pass rate. The useful read is product-specific, not vendor-wide. GHK-Cu is the cleanest observed product and Tirzepatide is comparatively defensible; Retatrutide needs current-batch verification, while Tesamorelin is the clear avoid signal. The full report shows how those calls shift under stricter grading.

The OSINT trail does not resolve Lumira into a clean public corporate owner. Instead, public records and site captures tie Lumira, Welon Peptide Solutions, and Peptidecube into the same operational cluster through Hong Kong contact identifiers, Welon branding, related marketplace profiles, and overlapping buyer channels. That linkage matters because US-based shipping language sits beside Hong Kong and Chinese-factory context, while public complaints describe dispatch delays and refund friction.

The digital and reputation stack is young and lightly accountable. Lumira.sale and welonpeptide.com are recent privacy-protected domains; Welon DNS points to budget shared-hosting infrastructure; no founder, executive team, LinkedIn company page, or verified personnel map surfaced. A promotion scan also found a referral-code-heavy Peptaura/Lumira network with sparse clear disclosure, including coupon amplification and an operator-style restock post carrying batch-confidence claims.

Bottom line: Lumira is not uniformly unusable, but it is a poor fit for buyers who need clean domestic fulfillment, strong post-payment recourse, or Tesamorelin without independent batch testing. For GHK-Cu and Tirzepatide, the lab signal is more defensible; for Retatrutide, the decision turns on exact-batch proof.

Inside the full report:

  • Per-product pass/fail rates and methodology-divergence charts for all 4 tested products
  • Dated evidence timeline from domain registrations through Peptaura marketplace activity
  • Identity map linking Lumira, Welon Peptide Solutions, and Peptidecube through address, phone, emails, and branding
  • WHOIS and DNS exhibits for lumira.sale and welonpeptide.com, including Hostinger infrastructure
  • Affiliate-promotion matrix covering 14 promoter leads, referral codes, and disclosure status
  • Payment/refund-friction analysis with Reddit COA and shipping-complaint exhibits

Risk assessment

  • Geographic/fulfillment misrepresentation risk — high: Welon US-based shipping claims conflict with Hong Kong/Chinese-factory records and public reports of 11-12 day dispatch delays.
  • Tesamorelin quality-control risk — high: Lumira Tesamorelin has 5 tests, 3 pass / 2 fail, and a Finnrick rating of 49.5%; avoid absent batch-level independent verification.
  • Retatrutide consistency risk — medium: Lumira Retatrutide has 11 tests, 8 pass / 3 fail, and a Finnrick rating of 75.81%; use only with current-batch verification.
  • Brand-confusion and corporate-accountability risk — medium: Lumira/Welon/Peptidecube share Hong Kong identifiers, recent privacy-protected domains, and no verified public corporate/personnel record surfaced.
  • Affiliate-promotion risk — medium: Promotion scan found 14 promoters; 13 carried referral code/link signals, while clear disclosure was visible for only 2.
  • Payment and refund-friction risk — medium: Payment methods are vaguely described; public complaints mention Alibaba/WhatsApp-style transactions and refund delays tied to freight-forwarder confirmation.